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ABSTRACT
Objective  To assess the safety and effectiveness of 
imatinib mesylate in the treatment of diffuse cutaneous 
systemic sclerosis (dcSSc).
Methods  In this phase IIa, open-label, single-arm clinical 
trial, 30 patients with dcSSc were treated with imatinib 
400 mg daily. Patients were monitored monthly for safety 
assessments. Modiﬁ  ed Rodnan skin scores (MRSS) were 
assessed every 3 months. Pulmonary function testing, chest 
radiography, echocardiography and skin biopsies were 
performed at baseline and after 12 months of treatment.
Results  Twenty-four patients completed 12 months of 
therapy. 171 adverse events (AE) with possible relation 
to imatinib were identiﬁ  ed; 97.6% were grade 1 or 2. 
Twenty-four serious AE were identiﬁ  ed, two of which 
were attributed to study medication. MRSS decreased 
by 6.6 points or 22.4% at 12 months (p=0.001). This 
change was evident starting at the 6-month time point 
(Δ=−4.5; p<0.001) and was seen in patients with both 
early and late-stage disease. Forced vital capacity (FVC) 
improved by 6.4% predicted (p=0.008), and the diffusion 
capacity remained stable. The improvement in FVC was 
signiﬁ  cantly greater in patients without interstitial lung 
disease. Health-related quality of life measures improved 
or remained stable. Blinded dermatopathological analysis 
conﬁ  rmed a signiﬁ  cant decrease in skin thickness and 
improvement in skin morphology.
Conclusions  Treatment with imatinib was tolerated 
by most patients in this cohort. Although AE were 
common, most were mild to moderate. In this open-label 
experience, improvements in skin thickening and FVC 
were observed. Further investigation of tyrosine kinase 
inhibition for dcSSc in a double-blind randomised placebo 
controlled trial is warranted.
ClinicalTrials.gov, NCT00555581
Systemic sclerosis (SSc) is a multisystem, ﬁ  bros-
ing disorder in which vasculopathy, autoimmunity 
and inﬂ  ammation lead to morbidity and increased 
mortality.1 Abnormal signalling through the trans-
forming growth factor beta (TGFβ)2–4 and the plate-
let-derived growth factor5–8 axes contributes to this 
pathological ﬁ  brosis. Imatinib mesylate (Gleevec; 
Novartis Pharmaceuticals, Basel, Switzerland) is 
a tyrosine kinase inhibitor with activity against 
c-Abl, the platelet-derived growth factor receptor 
(PDGFR), and other tyrosine kinases and is a ther-
apy of interest for SSc because of its ability to inter-
fere with both TGFβ and platelet-derived growth 
factor signalling.9 10
Combined inhibition of both TGFβ and PDGFR 
signalling by imatinib has been shown to decrease 
the production of extracellular matrix proteins by 
both scleroderma and normal skin ﬁ  broblasts.11 In 
murine models of both early and established cutane-
ous ﬁ  brosis and pulmonary ﬁ  brosis, imatinib treat-
ment was beneﬁ  cial.11–14 Similar effects were seen 
with nilotinib and dasatinib, other tyrosine kinase 
inhibitors that also block c-abl and PDGFR.15
Case reports of the use of imatinib in patients 
with SSc16–18 and mixed connective tissue disease19 
have suggested clinical beneﬁ   t. In case series of 
other cutaneous ﬁ   brosing disorders, nephrogenic 
systemic ﬁ  brosis20 and chronic sclerodermatous 
graft versus host disease,21 22 imatinib also showed 
a potential antiﬁ  brotic effect on the skin. However, 
in a randomised, placebo controlled study of ima-
tinib for idiopathic pulmonary ﬁ  brosis treatment 
was not beneﬁ  cial.23
We report here the results of a single-centre, phase 
IIa, single-arm, open-label clinical trial assessing the 
safety and efﬁ  cacy of imatinib in the treatment of 
diffuse cutaneous systemic sclerosis (dcSSc).
PATIENTS AND METHODS
Study subjects
Between September 2007 and March 2009, 30 
patients were enrolled. All patients fulﬁ  lled  the 
American College of Rheumatology classiﬁ  ca-
tion criteria for SSc24 and had the diffuse sub-
type. Patients were stratiﬁ  ed by disease duration 
deﬁ  ned as onset of ﬁ  rst symptom of SSc apart from 
Raynaud’s phenomenon: group 1 (n=20) less than 4 
years and group 2 (n=10) 4–10 years.
All subjects were over 18 years old, had a stable 
modiﬁ  ed Rodnan skin score (MRSS) of 16 points 
or more in the month between screening and base-
line visits, and had disease duration of less than 10 
years. Exclusion criteria included treatment with 
immunosuppressive therapies 3 months before 
baseline (including prednisone equivalent >10 mg), 
pregnancy, serious medical conditions, diffusion 
capacity of carbon monoxide (DLCO) less than 
30% predicted, or ejection fraction (EF) less than 
50% (see supplementary material, available online 
only).
Study design
This was an investigator-initiated phase IIa, single-
centre, single-arm, open-label clinical trial. The 
primary objective of this study was to assess the 
safety and tolerability of imatinib in patients with 
dcSSc as assessed by the number of adverse events 
(AE) and serious adverse events (SAE). The primary 
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data, was also performed and was not different (not shown). 
In the case of missing data points, we utilised last observation 
carried forward. Paired t tests and Wilcoxon signed-rank tests 
were used to compare outcome measures before and after treat-
ment, and unpaired t tests were used for comparisons between 
groups of patients. Statistical analysis was performed using 
SPSS software version 17.0.
RESULTS
Fifty-three patients were screened, 35 met entry criteria and 
ﬁ  ve declined consent. Thirty patients started medication and 24 
completed the study protocol. Baseline characteristics of the 30 
subjects are summarised in table 1. Patients were categorised 
as having interstitial lung disease (ILD) if they had evidence of 
ground glass opacity and/or ﬁ  brosis on CT of the chest felt to be 
related to SSc in the opinion of the investigators and the treating 
physicians..
Three patients withdrew from the study in the ﬁ  rst  3 
months: two because of non-compliance and one developed 
efﬁ  cacy endpoint was change in the MRSS after 12 months of 
treatment. Secondary efﬁ   cacy endpoints included change in 
forced vital capacity (FVC) and DLCO on pulmonary function 
testing (PFT) after 1 year of treatment, change in the short form 
36 mental and physical components and change in scleroderma 
health assessment questionnaire disability index.
The protocol was approved by the institutional review board 
at the Hospital for Special Surgery and was conducted in accor-
dance with the Declaration of Helsinki and good clinical prac-
tice guidelines. Patients provided written informed consent 
before enrollment. An independent data and safety monitoring 
board regularly reviewed safety data. The trial was registered at 
ClinicalTrials.gov (NCT00555581).
Clinical outcomes
Patients were assessed at monthly visits for AE ascertainment, 
interval history, physical examination and clinical laboratories, 
and were to call our centre for issues between visits. AE were 
listed according to the National Cancer Institute’s common ter-
minology.25 The MRSS was measured at screening, 1 month 
later at baseline and every 3 months. MRSS measurements were 
performed by the same physician at each visit (RS or both RS 
and JKG) PFT with measurement of FVC and DLCO were per-
formed at baseline and following 12 months of therapy and are 
available on 22 completers.
Treatment
All patients were treated with imatinib at a target dose of 400 mg 
daily by mouth for 12 months. Dose modiﬁ  cations and interrup-
tions were made for AE and were recorded. After 12 months of 
treatment, imatinib was stopped for 3 months. Patients were 
reassessed and offered entrance to an extension phase of the 
trial.
Dermatopathology
Four-millimetre punch biopsies of lesional forearm skin were 
performed before and after 12 months of treatment in 24 com-
pleters. The post-treatment biopsy was taken 1 cm adjacent to 
the original biopsy. Nineteen pairs were bisected. Half were 
formalin-ﬁ   xed and parafﬁ   n-embedded, and half were stored 
for RNA extraction. The ﬁ  ve ﬁ  nal samples were prospectively 
reserved and submitted in entirety for RNA extraction to pre-
serve adequate RNA quantity for microarray and follow-up con-
ﬁ  rmatory studies. The six patients who did not complete the 
study did not have follow-up biopsies. Sections were stained 
with H&E, anti-α-smooth muscle actin, Masson trichrome and 
elastin using standard techniques. A dermatopathologist (CM), 
blinded to before or after treatment status, compared the paired 
specimens.
Statistical analysis
The primary endpoint was a description of AE and SAE, and for 
this descriptive data are provided. No power calculation was 
performed for safety measurements, because there was no sta-
tistical analysis to be performed without a comparison group. 
The MRSS was the primary efﬁ  cacy endpoint. Given a 5±8 unit 
difference in MRSS, based on a minimally clinically important 
difference of 5 points,26 a sample size of 30 was needed for a 
two-sided alpha of 0.05 and 90% power. Analysis of all patients 
remaining on medication and reaching efﬁ  cacy endpoints at 
months 3 (n=27), 6 (n=26), 9 (n=26) and 12 (n=24) is shown 
below as per our predeﬁ   ned protocol. A post-hoc modiﬁ  ed 
intent-to-treat analysis including all patients with follow-up 
Table 1  Baseline demographics, scleroderma related organ system 
involvement and previous treatments
Parameter  
Age, in years, median (range)
 Median 48
  Minimum, maximum 18, 71
Sex, n (%)
 Women 24  (80%)
 Men 6  (20%)
Race, ethnicity, n (%)
  White, non-Hispanic 22 (73%)
  White, Hispanic 4 (13%)
 African-American 4  (13%)
Disease duration, n, mean±SD
  Whole group, n=30 3.4±2.3 years
  Early group, n=20 (0–4 years) 2.1±1.2 years
  Later group, n=10 (4–10 years) 6.1±1.6 years
Anti-Scl70 positive, n (%) 9 (30%)
MRSS at baseline 30.3±8.7
Organ involvement, n (%)
 Gastrointestinal 28  (93%)
 ILD 16  (53%)
  Pulmonary artery Hypertension 3 (10%)
 Cardiac 3  (10%)
 Renal 1  (3%)
 Myopathy 10  (33%)
 Arthritis 22  (73%)
  Raynaud’s phenomenon 30 (100%)
  Digital ulceration 24 (80%)
Previous treatment, n (%)
 Corticosteroids 14  (46.7%)
 Methotrexate 9  (30.0%)
  Mycophenalate mofetil 6 (20.0%)
 Cyclophosphamide 5  (16.7%)
 Penicillamine 3  (10.0%)
 IVIG 3  (10.0%)
 Plaquenil 4  (13.3%)
 Colchicine 2  (6.7%)
 Thalidomide 2  (6.7%)
 Minocycline 2  (6.7%)
  Autologous stem cell transplant 1 (3.3%)
  Oral collagen 1 (3.3%)
 Phototherapy 3  (10%)
  No previous treatment 7 (23.3%)
ILD, interstitial lung disease; IVIG, intravenous immunoglobulin; MRSS, modiﬁ  ed Rodnan 
skin score.
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there was no apparent volume overload during the event; the 
death was not felt to be medication related. Thirteen of the 24 
SAE, including all seven hospitalisations for haemorrhagic cysti-
tis, occurred in a single patient and were primarily complications 
of previous treatment with high-dose cyclophosphamide with 
autologous stem cell transplant. The haemorrhagic cystitis was 
a pre-existing problem before trial entry. One imatinib-related 
SAE was ﬂ  uid overload with bilateral pleural effusions, which 
required hospitalisation for diuresis. This episode occurred 
in the context of the patient receiving ﬂ  uid resuscitation for a 
severe haemorrhoidal bleed. The patient subsequently tolerated 
reintroduction and treatment with imatinib 300 mg daily with 
concomitant furosemide administration.
Chest radiography and echocardiography
Postero-antero and lateral chest radiographs and transthoracic 
two-dimensional echocardiograms were performed at baseline 
and after 12 months of treatment. Twenty-three of 24 chest 
radiographs were unchanged. One patient with ILD developed 
increased inﬁ  ltrates on the follow-up study, which was further 
evaluated with high resolution CT and found to be unchanged 
from baseline.
Three patients had echocardiographic changes during the 
course of the trial, two of which were of clinical signiﬁ  cance. One 
patient, who did not complete the trial, developed cardiomyopa-
thy with congestive heart failure at a point when she had largely 
discontinued the medication. The patient’s treating physicians felt 
the cardiomyopathy was a result of ischaemic heart disease and 
was tachyarrhythmia mediated, and the investigators attributed 
this SAE as possibly related to imatinib. Two additional patients 
had declines in EF as noted on surveillance echocardiography 
from baseline normal EF to EF of 50–55%. One patient followed 
up with a cardiac MRI and was found to have a normal EF of 
60%. The other patient underwent a multigated image acquisi-
tion scan, which conﬁ  rmed the decline in EF. This patient had 
experienced disease progression in pulmonary, gastrointestinal 
and cutaneous manifestations, and the cardiomyopathy was felt 
to be most likely related to the progression of disease.
Modiﬁ  ed Rodnan skin score
There was a signiﬁ  cant improvement of the MRSS over the 
course of 1 year with treatment with imatinib. At 12 months 
an inﬂ  ammatory myopathy that required immunosuppression. 
One patient withdrew after 3 months because of myalgia and 
fatigue, and one patient withdrew after 11 months because of 
the development of multiple medical issues (described below). 
One patient died after 11 months on medication. Safety data are 
included on all 30 patients enrolled.
Safety outcomes
Adverse events
There were 358 total AE captured during the study period, of 
which 171 were considered to be possibly, probably, or deﬁ  nitely 
related to imatinib. All AE at least possibly related to imatinib 
and occurring in more than one patient are presented in table 2. 
Of these 171 AE, 72.5% were grade 1, 25.1% were grade 2 and 
2.4% were grade 3 or 4 in severity. The most common AE was 
oedema, which was seen in 80% of patients. Fluid-related issues 
required the addition of furosemide in 60% of patients and dose 
adjustment in 30%. All AE captured regardless of attribution are 
presented as supplementary material, available online only.
Eighty-three per cent of patients required dose adjustment at 
least one time, and the median dose taken as assessed by both 
pill count and patient report was 300 mg daily. The leading 
causes for dose adjustment or interruption were musculoskeletal 
complaints in 36.7%, ﬂ  uid-related issues in 26.7%, intercurrent 
illness in 23.3%, gastrointestinal complaints in 23.3% and con-
stitutional symptoms in 20% of patients.
Creatine kinase (CK) elevations greater than 1.5 times the 
baseline CK value without change in strength were seen in 43% 
of patients. Elevation of CK has been recognised in patients 
with chronic myeloid leukaemia (CML) and gastrointestinal 
stromal tumour with imatinib therapy.27 28 One patient, who 
had discontinued methotrexate 3 months before study entry, 
experienced increased proximal muscle weakness accompanied 
by an increased CK from 320 to 468 after 4 weeks on proto-
col. Electromyography showed inﬂ  ammatory myopathy, and 
the patient was withdrawn from the study to be treated with 
immunosuppressive agents.
Serious adverse events
There were 24 SAE (table 2). One patient with severe ILD and 
pulmonary artery hypertension died from pneumonia and respi-
ratory failure. As the patient was not neutropenic, had tolerated 
imatinib without evidence of ﬂ  uid overload for 11 months, and 
Table 2  AE at least possibly related to imatinib, ocurring in more than one patient and all SAE
AE with possible relation SAE
Event % Event No of events (no of patients) Attribution
Oedema 80 Haematuria (hospitalisations) 7 (1) Not related
Nausea 73 Pneumonia 2 (2) Unlikely
Myalgias 67 C difﬁ  cile infection 2 (1) Not related
CK elevation 43 Infected ulcer 2 (2) Unlikely
Fatigue 40 Death (pneumonia) 1 (1) Not related
Anaemia 27 Acute gastroenteritis 1 (1) Not related
Pyrosis 13 Acute myocardial infarction 1 (1) Not related
Vomiting 13 Anaemia blood transfusion 1 (1) Not related
Weight loss 13 Fall 1 (1) Not related
Headaches 13 Fluid overload 1 (1) Probably
Effusions 10 Rectal prolapse, haemorrhoidal bleed 1 (1) Unlikely
Hypocalcemia 7 Nephrolithiasis 1 (1) Not related
Dry skin 7 Partial small bowel obstruction 1 (1) Not related
Erectile dysfunction 7 Bleeding post renal biopsy (hospitalisation) 1 (1) Not related
Generalised weakness 7 Tachyarrhythmia/cardiomyopathy 1 (1) Possibly
Light-headedness 7      
AE, adverse event; CK, creatine kinase; SAE, serious adverse event.
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but there was no difference between the groups with respect 
to the change in DLCO (p=0.19; table 4). Differences were not 
seen in PFT changes based on disease duration or based on anti-
scl70 status.
Additional outcomes
Outcomes regarding health-related quality of life measures 
are shown in table 4, with signiﬁ  cant improvements or stabil-
ity in multiple parameters. There was no correlation between 
change in FVC and change in MRSS (Spearman’s rank correla-
tion −0.071).
Dermatopathology
The median skin thickness decreased with treatment from 2.23 
mm (IQR 2.0–2.95) to 2.0 mm (1.81–2.36) as measured from 
the granular cell layer to the dermal subcutaneous interface or 
the greatest depth on H&E (p<0.01). There was a signiﬁ  cant 
increase in the number of appendageal structures (hair follicles 
plus eccrine glands) counted per vertical section from two (one 
to four) to three (two to six); p=0.03. All specimens before treat-
ment exhibited changes typical of scleroderma including thick 
and hyalinised collagen bundles with decreased interstitial 
spaces. Nine of the pretreatment specimens exhibited artefact 
from overﬁ  xation, which precluded comparative assessment 
with the post-treatment specimen. Of the 10 assessable speci-
mens, seven exhibited a qualitative decrease in the thickness 
of collagen bundles and increase in interstitial spaces (ﬁ  gure 2). 
One specimen had increased sclerodermatous characteristics 
and two were unchanged. The morphological differences cor-
responded to MRSS improvement with the mean change in 
MRSS in the group with histological improvement being −8.8 
of treatment, the mean MRSS improved from 29.42±8.6 to 
22.8±10.2 (p<0.001) and the mean difference in MRSS was −6.6 
points (95% CI −4.5 to −8.7). This change was not seen after 3 
months of treatment, but was evident at 6 months, with a mean 
improvement of −4.5 points (−2.6 to −6.5; p<0.001) and at 9 
months with a mean improvement of −5.3 points (−3.5 to −7.1; 
p<0.001; ﬁ  gure 1).
Similar improvements in MRSS were seen across different 
durations of disease. In a post hoc analysis of patients with early 
disease of less than 18 months’ duration (n=8), there was a sig-
niﬁ  cant improvement of 7.9±5.7 points (p=0.006; table 3). There 
were no differences in change in MRSS between disease dura-
tion subgroups whether 18 months or 4 years was used as the 
cut-off for deﬁ  ning ‘early’ disease. There was no difference in 
change in MRSS between patients who were anti-Scl70 positive 
versus those who were anti-Sc170 negative.
Pulmonary function testing
FVC improved from a mean of 82.9±21.1% to 89.3±25.2% pre-
dicted (p=0.008). The mean DLCO trended from 78.0±22.9 % 
to 83.5±29.2% predicted (p=0.12; ﬁ  gure 2A,B). When patients 
were subcategorised by the presence or absence of ILD, those 
with ILD remained stable with respect to their FVC and DLCO, 
with an average increase in FVC of 2.1% points (95% CI −2.9 
to 7.0; p=0.36) and an average increase in DLCO of 1.0% 
points (−8.0 to 10.1; p=0.81). Those without ILD improved 
with respect to their FVC, with an average increase of 10.7% 
points (−3.3 to 18.2; p=0.01), and remained stable with respect 
to their DLCO, with an average change of +9.9% points (−1.7 
to 21.5; p=0.09). Patients without ILD had a greater improve-
ment in their change in FVC than did those with ILD (p=0.043) 
Figure 1  Modiﬁ  ed Rodnan skin score (MRSS) over the duration of the trial in all patients on treatment. At baseline the MRSS was 30.3±8.7 
(n=30). After 3 months of imatinib therapy the MRSS was 29.9±9.4 compared with a baseline mean of 30.4±9.1 in this group (n=27); p=0.428. 
After 6 months the MRSS was 26.1±9.1; p<0.001 compared with baseline mean of 30.6±9.2 in this group (n=26). After 9 months the MRSS was 
25.3±9.7; p<0.001 (n=26). After 12 months of treatment the mean MRSS was 22.8±10.2 compared with a baseline MRSS of 29.4±8.6 in this 
group (n=24); p<0.001. (A) As bar chart and (B) as individual patient plots. Black line is mean trendline.
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making attribution of improvements in clinical outcomes as well 
as of AE and SAE uncertain. Furthermore, this was a hetero-
geneous population in terms of disease duration, organ system 
involvement and previous treatment history, making it difﬁ  cult 
to compare this experience with trials including only early active 
SSc patients.
While patients in our trial had relatively early disease (mean 
disease duration 3.4 years), we prospectively elected to enroll 
10 patients with later disease (4–10 years), appreciating that 
this subgroup is also in need of better therapies. Their inclu-
sion in this pilot study was necessary to establish the tolerability 
and safety of this potentially antiﬁ  brotic therapy in later-stage 
patients, which would be requisite for their inclusion in future 
controlled studies. We recognise that including this subgroup 
adds to the difﬁ   culty in interpreting the signiﬁ   cance of the 
improvements observed in our trial. Encouragingly, however, 
similar improvements were also seen in patients with very early 
(<18 months) disease duration. Nevertheless, deﬁ  nitive conclu-
sions regarding efﬁ  cacy cannot be drawn from an open-label 
(−6 to −12), the unchanged biopsies had MRSS changes of −1 
and −5, and the patient whose biopsy looked worse had an 
MRSS of +4. Eight before and after pairs stained adequately 
with anti-α-smooth muscle actin. Of these, three showed 
decreased ﬁ   brocyte staining after treatment, one showed 
increased staining and four were unchanged. No differences 
were discernible with elastin or Masson trichrome staining.
DISCUSSION AND CONCLUSIONS
Tyrosine kinase inhibition has emerged as a therapeutic 
approach of interest in scleroderma and other ﬁ  brosing disor-
ders. This study represents the largest prospective trial of ima-
tinib in dcSSc reported to date. Our results indicate acceptable 
safety and tolerability, and suggest the potential efﬁ  cacy  of 
imatinib for cutaneous and pulmonary manifestations of dcSSc, 
as well as beneﬁ  t in patient-derived subjective outcomes. The 
strengths of this study include the number of patients treated, its 
prospective design and its relatively long duration. The obvious 
weakness is the open-label design and lack of a control group, 
Figure 2  (A–D) Depicted are skin biopsy specimens before and after 12 months of imatinib therapy in a single patient at 4× magniﬁ  cation. (A and 
B). H&E: After treatment there was a decrease in skin thickness. In the post-treatment specimen the collagen bundles are less thick and there is an 
increase in the interstitial spaces between the bundles. There are also increased numbers of adnexal structures in the post-treatment specimen. This 
individual patient is anti-Scl70 positive, with a disease duration of 4 months at baseline who had an improvement in MRSS of 9 points over the course 
of 12 months. In C and D are depicted anti-α-smooth muscle actin staining before treatment in panel C and post-treatment in D, showing a decline in 
the intensity of staining.
Table 3  Change in MRSS by disease duration
Subgroup (n)
MRSS at baseline 
mean (SD)
MRSS at 12 
months mean (SD)
Mean change in 
MRSS (SD) p Value
% Change 
in MRSS
Duration of disease <18 months (n=8) 26.8 (9.6) 18.9 (11.6) −7.9 (5.2) 0.006 −29.5
Duration of disease <4 years (n=17) 28.8 (9.0) 23.0 (11.2) −5.8 (5.1) <0.001 −20.1
Duration of disease 4–10 years (n=7) 30.9 (7.9) 22.3 (8.0) −8.6 (4.1) 0.001 −27.8
All completers (n=24) 29.4 (8.6) 22.8 (10.2) −6.6 (4.7) <0.0001 −22.4
MRSS, modiﬁ  ed Rodnan skin score.
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efﬁ  cacy were observed in MRSS, FVC and patient-derived qual-
ity of life indices. These ﬁ  ndings cannot be deﬁ  nitively attrib-
uted to medication effect in an uncontrolled trial but deserve 
further investigation. A prospective randomised, double-blind, 
placebo controlled trial is warranted to deﬁ   ne more clearly 
whether there is a role for tyrosine kinase inhibition in the treat-
ment of dcSSc.
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experience, especially noting that spontaneous improvements in 
skin scores can be seen even in patients with early stage dcSSc in 
clinical trials29 or observational studies.30 Although the blinded 
dermatopathological assessments support our clinical ﬁ  ndings, 
attribution of these improvements to treatment is uncertain 
without a longitudinal control group.
A large number of AE and SAE were recognised during this 
1-year trial, which may relate in part to our patients’ signiﬁ  -
cant disease burden. However, 80% of patients enrolled were 
able to complete a full year of therapy. This number com-
pares favourably to what has been observed in other clini-
cal trials in scleroderma,31–34 but not surprisingly is less than 
what has been seen in trials of CML.35 Oedema, myalgia and 
fatigue were frequent side effects, but were manageable, and 
infrequently led to withdrawal from our study. Cardiac tox-
icity has been reported as a rare complication of imatinib in 
CML, particularly in patients with concurrent risk factors for 
cardiomyopathy,36 making it an important concern in SSc. Two 
patients in our study did develop cardiac issues that were not 
felt to be likely related to imatinib given the individuals’ clini-
cal contexts; nevertheless, vigilance for this potential complica-
tion is prudent.
Our recognition of improvement in indices of pulmonary 
function during this 1-year trial is of unclear signiﬁ  cance. There 
was a statistically signiﬁ  cant improvement in FVC and stabi-
lisation of DLCO at 1 year. However, not all of our patients 
had ILD, and the clinical signiﬁ  cance of this improvement37 in 
patients without appreciable ILD at baseline is uncertain. One 
possible explanation is that this observed improvement in FVC 
may relate to amelioration of chest wall tightening rather than 
effects on parenchymal lung disease. Importantly, a randomised 
double-blind placebo controlled trial in idiopathic pulmonary 
ﬁ  brosis did not show beneﬁ  t of imatinib therapy.36
In conclusion, this study represents the largest and longest 
open-label trial of imatinib in SSc. Side effects were common, 
but most patients tolerated the medication. Signals of potential 
Table 4 Outcome  measures
Outcome measure (n) Baseline mean (SD) Month 12 mean (SD) Mean change (95% CI) p Value
MRSS (24) 29.4 (8.6) 22.8 (10.2) −6.6 (−4.5 to −8.7) <0.001
PFT All (22)
  FVC % predicted 82.9 (21.1) 89.3 (25.2) 6.4 (1.9 to 10.9) 0.008
  DLCO Hb adj % predicted 78.0 (22.9) 83.5 (29.2) 5.5 (−1.5 to 12.4) 0.12
PFT ILD (11)
  FVC % predicted 73.3 (18.3) 75.4 (20.7) 2.1 (−2.8 to 7) 0.36
  DLCO Hb adj % predicted 64.7 (14.0) 65.7 (15.6) 1.0 (−8.1 to 10.1) 0.81
PFT not ILD (11)
  FVC % predicted 92.6 (19.8) 103.2 (21.8) 10.7 (3.3 to 18.2) 0.01
  DLCO Hb adj % predicted 91.3 (22.8) 101.2 (29.2) 9.9 (−1.7 to 21.5) 0.09
HRQoL (24)
  VAS global 46.7 (22.4) 37.1 (28.2) −9.6 (0.2 to 19.0) 0.046
  VAS SOB 19.6 (24.2) 12.8 (24.6) −6.7 (2.0 to 11.5) 0.008
  VAS pain 49.5 (27.4) 30.8 (29.7) −18.7 (9.7 to 27.8) <0.001
  VAS RP 37.3 (28.7) 30.0 (28.9) −9.3 (−1.9 to 20.5) 0.098
  VAS digital ulcers 33.6 (37.8) 21.1 (28.5) −12.5 (−0.9 to 25.9) 0.066
  SHAQ-DI 1.1 (0.6) 1.1 (0.7) 0.02 (−0.15 to 0.18) 0.85
  SF-36 PC 46.8 (17.3) 53.5 (25.6) 6.8 (1.7 to 15.3) 0.11
  SF-36 MC 61.5 (15.8) 68.1 (18.6) −6.6 (−12.5 to −0.7) 0.03
Other
  PGA 6.3 (1.6) 4.1 (2.3) −2.2 (−2.9 to −1.4) <0.001
 ESR 25.6 (18.8) 22.1 (15.5) −3.5 (−4.0 to 11.0) 0.35
DLCO, diffusion capacity of carbon monoxide; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; Hb, haemoglobin; 
HRQoL, health-related quality of life; MC, mental component; MRSS, modiﬁ  ed Rodnan skin score; PC, physical component; 
PFT, pulmonary function test; PGA, physician global assessment; RP, Raynaud’s phenomenon; SF-36, short form 36; 
SHAQ-DI, scleroderma health assessment questionnaire disability index; SOB, shortness of breath; VAS, visual analogue scale.
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